GLPG0187 is a broad spectrumintegrinreceptor antagonist with antitumor activity; inhibits α_vβ₁-integrin with anIC₅₀of 1.3 nM^[1]. GLPG0187 inhibits migrasome biogenesis without cytotoxicity^[3].

IC50: 1.3 nM (α_vβ₁)^[1]

In a solid-phase assay, GLPG0187 shows selectivity for several RGD integrin receptors with IC₅₀s of 1.3, 3.7, 2.0, 1.4, 1.2, 7.7 nM for α_vβ₁, α_vβ₃, α_vβ₅, α_vβ₆,α_vβ₈, and α₅β₁. GLPG0187 is a potent inhibitor of osteoclastic bone resorption and angiogenesis. Treatment with GLPG0187 dose-dependently increases the E-cadherin/vimentin ratio, rendering the cells a more epithelial, sessile phenotype. GLPG0187 dose-dependently diminishes the size of the aldehyde dehydrogenase high subpopulation of prostate cancer cells^[1]. GLPG0187 treatment results in cell rounding and clumping. GLPG0187 demonstrates a dose-dependent significant reduction in tumour cell migration. GLPG0187 at all concentrations significantly reduces cell proliferation^[2].

Blocking α_v-integrins by GLPG0187 markedly reduces their metastatic tumor growth. Bone tumor burden is significantly lower and the number of bone metastases/mouse is significantly inhibited. The progression of bone metastases and the formation of new bone metastases during the treatment period is significantly inhibited^[1].

595.71

Solid

C₂₉H₃₇N₇O₅S

1320346-97-1

Room temperature in continental US; may vary elsewhere.

DMSO : 12.5 mg/mL(20.98 mM;ultrasonic and warming and heat to 60℃)

H₂O :< 0.1 mg/mL (ultrasonic;warming;heat to 60℃)(insoluble)

请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的半岛bd体育手机客户端 失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 20%HP-β-CDin saline

  Solubility: 10 mg/mL (16.79 mM); Suspension solution; Need ultrasonic
• 2.

  请依序添加每种溶剂： 10% DMSO40%PEG3005%Tween-8045% saline

  Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution

  此方案可获得 ≥ 1.25 mg/mL (2.10 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 3.

  请依序添加每种溶剂： 10% DMSO90%corn oil

  Solubility: ≥ 1.25 mg/mL (2.10 mM); Clear solution

  此方案可获得 ≥ 1.25 mg/mL (2.10 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

• 4.

  请依序添加每种溶剂： 5% DMSO40%PEG3005%Tween-8050% saline

  Solubility: ≥ 0.89 mg/mL (1.49 mM); Clear solution
• 5.

  请依序添加每种溶剂： 5% DMSO95% (20%SBE-β-CDin saline)

  Solubility: ≥ 0.89 mg/mL (1.49 mM); Clear solution